Lucid Diagnostics (NASDAQ:LUCD) versus Upstream Bio (NASDAQ:UPB) Critical Comparison

Upstream Bio (NASDAQ:UPB) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Institutional and Insider Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. 16.5% of Upstream Bio shares are held by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Upstream Bio and Lucid Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Lucid Diagnostics	-959.76%	N/A	-119.57%

Analyst Ratings

This is a breakdown of current ratings and target prices for Upstream Bio and Lucid Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1	2	4	0	2.43
Lucid Diagnostics	1	0	4	0	2.60

Upstream Bio presently has a consensus price target of $29.67, suggesting a potential upside of 824.20%. Lucid Diagnostics has a consensus price target of $4.19, suggesting a potential upside of 973.72%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe Lucid Diagnostics is more favorable than Upstream Bio.

Risk and Volatility

Upstream Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Lucid Diagnostics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Earnings & Valuation

This table compares Upstream Bio and Lucid Diagnostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85 million	61.69	-$143.44 million	($2.90)	-1.11
Lucid Diagnostics	$4.71 million	16.83	-$58.01 million	($0.47)	-0.83

Lucid Diagnostics has higher revenue and earnings than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

Lucid Diagnostics beats Upstream Bio on 8 of the 12 factors compared between the two stocks.

About Upstream Bio

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

About Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.